A New Standard of Care for Small Cell Lung Cancer?
December 12th 2023Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.
Read More
Pirtobrutinib Shows Activity in Relapsed/Refractory MCL After Covalent BTK Inhibitor Therapy
December 12th 2023Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Read More
BGB-16673 Shows Responses With a Manageable Safety Profile Across R/R B-Cell Malignancies
December 12th 2023The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.
Read More
Daratumumab Plus VRd Betters PFS in Transplant-Eligible, Newly Diagnosed Multiple Myeloma
December 12th 2023Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant and D-VRd consolidation and daratumumab/lenalidomide maintenance significantly prolonged progression-free survival.
Read More
Talquetamab Dose Modifications Maintain Efficacy, Lower AEs for Myeloma
December 12th 2023Dose reductions of the GPRC5D/CD3 bispecific antibody talquetamab effectively improved on-target adverse events while sustaining high response rates for patients with relapsed/refractory multiple myeloma.
Read More
Pelabresib/Ruxolitinib Combo Betters Splenomegaly, TSS in JAK Inhibitor-Naive MF
December 11th 2023Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor-naive myelofibrosis.
Read More
Zanubrutinib Shows Viability After Intolerance to Acalabrutinib in B-Cell Malignancies
December 11th 2023Results from an ongoing phase 2 study show the viability for the use of zanubrutinib after patients with previously treated B-cell malignancies are deemed intolerant to the next-generation Bruton tyrosine kinase inhibitor acalabrutinib.
Read More
Brentuximab Combo Demonstrates Positive Efficacy in Advanced Hodgkin Lymphoma
December 11th 2023Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine appears to be well tolerated in patients with advanced stage classical Hodgkin lymphoma, according to data from the phase 2 SGN35-027 trial.
Read More
Ruxolitinib Confers Improved Control of Steroid Refractor/Dependent cGVHD
December 11th 2023The 3-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid refractory or dependent chronic graft-versus-host disease benefited more with ruxolitinib compared with best available treatment.
Read More
Dose-Escalation/Expansion Trial Evaluates NX-1607 Across Cancer Settings
December 11th 2023An ongoing phase 1a/1b trial is set to evaluate NX-1607-101, an oral small-molecule inhibitor of casitas B-lineage lymphoma B designed to enhance innate and adaptive immune responses and demonstrate antitumor activity and long-term survival in patients with persistent lymphoma including those with diffuse large B-cell lymphoma.
Read More
Acalabrutinib Combination, Monotherapy Improves PFS in Treatment-Naive CLL
December 11th 2023Acalabrutinib-containing regimens continued to improve progression-free survival, especially when a complete response is obtained, compared with obinutuzumab plus chlorambucil, in treatment-naive patients with chronic lymphocytic leukemia, according to a 6-year follow-up.
Read More
Axatilimab Shows Responses With Tolerable Safety in Recurrent/Refractory cGVHD
December 11th 2023Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.
Read More